• 1
    Beavo J.A., Brunton L.L. (2002) Cyclic nucleotide research – still expanding after half a century. Nat Rev Mol Cell Biol;3:710718.
  • 2
    Claveau D., Chen S.L., O’Keefe S., Zaller D.M., Styhler A., Liu S., Huang Z., Nicholson D.W., Mancini J.A. (2004) Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-{2-(3,4-bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther;310:752760.
  • 3
    Huang Z., Mancini J.A. (2006) Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. Curr Med Chem;13:32533262.
  • 4
    Zhang K.Y.J., Ibrahim P.N., Gillette S., Bollag G. (2005) Phosphodiesterase-4 as a potential drug target. Expert Opin Ther Targets;9:12831305.
  • 5
    Burnouf C., Pruniaux M.P. (2002) Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des;8:12551296.
  • 6
    Kodimuthali A., Jabaris S.S., Pal M. (2008) Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. J Med Chem;51:54715489.
  • 7
    Gopalan B., Gharat X., Lakdawala A.D., Karunakaran U. (2004) WO patent application 2004/089940.
  • 8
    Chakraborti A.K., Sarin S., Rudrawar S.V., Kumar R., Chankeshwara S.V., Ray A., Dastidar S.G. (2008) US patent 2008/0207659.
  • 9
    Houslay M.D., Schafer P., Zhang K.Y. (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today;10:15031519.
  • 10
    Bundschuh D.S., Eltze M., Barsig J., Wollin L., Hatzelmann A., Beume R. (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther;297:280290.
  • 11
    Burnouf C., Pruniaux M.-P., Szilagyi C.M., James A.B. (1998) Phosphodiesterases 4 inhibitors. Annu Rep Med Chem;33:91109.
  • 12
    Lipworth B.J. (2005) Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet;365:167175.
  • 13
    Rabe K.F., Bateman E.D., O’Donnell D., Witte S., Bredenbroker D., Bethke T.D. (2005) Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet;366:563571.
  • 14
    Wang P., Wu P., Ohleth K.M., Egan R.W., Billah M.M. (1999) Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol;56:170174.
  • 15
    Horowski R., Sastre-Y-Hernandez M. (1985) Clinical effects of the neurotrophic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr Ther Res;38:2329.
  • 16
    Donnell J.M. (2000) William harvey research conference on PDE inhibitors: drugs with an expanding range of therapeutic uses. Expert Opin Investig Drugs;9:621625.
  • 17
    Keshavarzian A., Mutlu E., Guzman J.P., Forsyth C., Banan A. (2007) Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. Expert Opin Investig Drugs;16:14891506.
  • 18
    Vu C.B., Corpuz E.G., Merry T.J., Pradeepan S.G., Bartlett C., Bohacek R.S., Botfield M.C., Eyermann C.J., Lynch B.A., MacNeil I.A., Ram M.K., van Schravendijk M.R., Violette S., Sawyer T.K. (1999) Discovery of potent and selective SH2 inhibitors of the tyrosine kinase zap-70. J Med Chem;42:40884098.
  • 19
    Orlek B.S., Blaney F.E., Brown F., Clark M.S., Hadley M.S., Hatcher J., Riley G.J., Rosenberg H.E., Wadsworth H.J., Wyman P. (1991) Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor. J Med Chem;34:27262735.
  • 20
    Clitherow J.W., Beswick P., Irving W.J., Scopes D.I.C., Barnes J.C., Clapham J., Brown J.D., Evans D.J., Hayes A.G. (1996) Novel 1, 2, 4-oxadiazoles as potent and selective histamine H3 receptor antagonists. Bioorg Med Chem Lett;6:833838.
  • 21
    Nicolaides D.N., Fylaktakidou K.C., Litinas K.E., Hadjipavlou-Litina D. (1998) Synthesis and biological evaluation of several coumarin-4-carboxamidoxime and 3-(coumarin-4-yl)-1,2,4-oxadiazole derivatives. Eur J Med Chem;33:715724.
  • 22
    Matsumoto J., Takahashi T., Agata M., Toyofuku H., Sasada N. (1994) A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor. Jpn J Pharmacol;65:5157.
  • 23
    Zhang H.Z., Kasibhatla S., Kuemmerle J., Kemnitzer W., Ollis-Mason K., Qiu L., Crogan-Grundy C., Tseng B., Drewe J., Cai S.X. (2005) Discovery and structure-activity relationship of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers and potential anticancer agents. J Med Chem;48:52155223.
  • 24
    Kumar D., Patel G., Johnson E.O., Shah K. (2009) Synthesis and anticancer activities of novel 3,5-disubstituted-1,2,4-oxadiazoles. Bioorg Med Chem Lett;19:27392741.
  • 25
    Chimirri A., Grasso S., Monforte A.M., Rao A., Zappala M. (1996) Synthesis and antitumor activity evaluation of delta2-1,2,4-oxadiazoline derivatives. Farmaco;51:125129.
  • 26
    Luthman K., Borg S., Hacksell U. (1999) Synthesis and use of pseudopeptides derived from 1,2,4-oxadiazole, 1,3,4-oxadiazole and 1,2,4-triazole based dipeptidomimetics. Methods Mol Med;23:123.
  • 27
    Borg S., Vollinga R.C., Labarre M., Payza K., Terenius L., Luthman K. (1999) Design, synthesis, and evaluation of phe-gly mimetics: heterocyclic building blocks for pseudopeptides. J Med Chem;42:43314342.
  • 28
    Borg S., Estenne-Bouhtou G., Luthman K., Csoeregh I., Hesselink W., Hacksell U. (1995) Synthesis of 1,2,4-oxadiazole-, 1,3,4-oxadiazole-, and 1,2,4-triazole-derived dipeptidomimetics. J Org Chem;60:31123120.
  • 29
    Wang J.-Q., Gao M., Miller K.D., Sledge G.W., Zheng Q.-H. (2006) Synthesis of [11c]Iressa as a new potential pet cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett;16:41024106.
  • 30
    Wang E.-C., Lin G.-J. (1998) A new one pot method for the conversion of aldehydes into nitriles using hydroxyamine and phthalic anhydride. Tetrahedron Lett;39:40474050.
  • 31
    Shibata M., Ohkubo T., Takahashi H., Inoki R. (1989) Modified formalin test: characteristic biphasic pain response. Pain;38:347352.
  • 32
    Winter C.A., Risley E.A., Nuss G.W. (1962) Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med;111:544547.
  • 33
    Chakraborti A.K., Kaur G. (1999) One-pot synthesis of nitriles from aldehydes under microwave irradiation: influence of the medium and mode of microwave irradiation on product formation. Tetrahedron;55:1326513268.
  • 34
    Chakraborti A.K., Kaur G., Roy S. (2001) A Simple and highly efficient one-pot chemoselective synthesis of nitriles from aldehydes: mechanistic insight and selectivity control through modulation of electronic and steric factors. Indian J Chem;40B:10001006.
  • 35
    Jiang X., Li J., Paskind M., Epstein P.M. (1996) Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc Natl Acad Sci USA;93:1123611241.
  • 36
    Ogawa R., Streiff M.B., Bugayenko A., Kato G.J. (2002) Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21WAF1/CIP1 proteins in human acute lymphoblastic leukemia cells. Blood;99:33903397.
  • 37
    Sekut L., Yarnall D., Stimpson S.A., Noel L.S., Bateman-Fite R., Clark R.L., Brackeen M.F., Menius J.A. Jr, Connolly K.M. (1995) Anti-inflammatory activity of phosphodiesterase (PDE)-iv inhibitors in acute and chronic models of inflammation. Clin Exp Immunol;100:126132.
  • 38
    Francischi J.N., Yokoro C.M., Poole S., Tafuri W.L., Cunha F.Q., Teixeira M.M. (2000) Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. Eur J Pharmacol;399:243249.